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A B S T R A C T
Shared decision making in advanced chronic kidney disease
(CKD) requires unbiased information on survival and
person-centred outcomes known to matter to patients: qual-
ity of life, symptom burden and support from family and
healthcare professionals. To date, when deciding between di-
alysis and conservative care, patients have had to rely on evi-
dence from small observational studies. Clinicians recognize
that like is not being compared with like in these studies,
and interpret the results differently. Furthermore, support
differs considerably between renal units. What patients
choose therefore depends on which renal unit they attend.
To address this, a programme of work has been underway
in the UK. After reports on survival and symptoms from a
small number of renal units, a national, mixed-methods
study—the Conservative Kidney Management Assessment of
Practice Patterns Study—mapped out conservative care prac-
tices and attitudes in the UK. This led to the Prepare for
Kidney Care study, a randomized controlled trial comparing
preparation for dialysis versus preparation for conservative
care. Although powered to detect a positivist 0.345 difference
in quality-adjusted life years between the two treatments,
this trial also takes a realist approach with a range of
person-centred secondary outcomes and embedded qualita-
tive research. To understand generalizability, it is nested in
an observational cohort study, which is nested in a CKD
registry. Challenges to recruitment and retention have been
rapidly identified and addressed using an established embed-
ded mixed methods approach—the QuinteT recruitment in-
tervention. This review considers the background to and
progress with recruitment to the trial.
Keywords: conservative care, comparative effectiveness, dialy-
sis, randomized controlled trial
I N T R O D U C T I O N
A range of integrated treatment options should be available for
estimated 4.9–9.7 million people who develop end-stage kidney
disease each year worldwide—haemodialysis (HD), peritoneal
dialysis (PD), transplantation and conservative care [1].
Reliable, stratified evidence of outcomes associated with each of
these modalities is needed, whether local culture dictates that it
is the patient, the family or the physician making the choice.
This article provides background to and presents the evolution
of a programme of work underway in the UK to provide more
robust evidence in one of these areas: the comparative effective-
ness of dialysis and conservative care in the frail older people
with multiple health conditions.
C H A L L E N G E S I N C O U N T I N G A N D Q U A L I T Y
A S S U R I N G T R E A T M E N T O F K I D N E Y F A I L U R E
Renal registries provide quality assurance for kidney replacement
therapy (KRT), but in the early weeks of treatment, ascertain-
ment bias is a problem (so some early deaths will be missed) [2]
and few registries include kidney failure treated without dialysis
[3]. Due to a lack of consensus on definitions, this latter group
has proven particularly difficult to count, but in high-income
countries is estimated to be 15% of all patients known to kid-
ney clinics [4, 5]. Less well studied is kidney failure not referred
to kidney clinics, but routine data from Canada and Australia
suggest that in the>85 years age group, there may be as many as
13 people not treated with KRT for everyone who is [6, 7].
D E F I N I N G C O N S E R V A T I V E C A R E
Treatment of kidney failure without dialysis—conservative
care—can be divided into three types: comprehensive conserva-
tive care, where treatment is chosen or medically advised;
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choice-restricted conservative care, where resource constraints
limit access to KRT; and unrecognized Stage 5 chronic kidney
disease (CKD) [8]. The first of these, comprehensive conserva-
tive care, is most relevant to this review and is defined as
‘planned holistic patient-centred care for patients with stage 5
CKD and including a full range of treatment and support, but
not dialysis’ [8].
So, if comprehensive conservative care is patient-centred, we
must consider what matters to patients approaching the end of
their lives. In a European, seven-country, telephone survey of
>9000 people (median age 50 years, interquartile rage 40–62),
most prioritized quality of life over survival (from 57% in Italy
to 81% in Spain), including those with advanced illness [9]. In
this study, only 2–6% of patients in countries said that extend-
ing life was most important, and this did not vary according to
the respondent’s health status [9]. More specifically, a system-
atic review of the literature by Parker et al. found that while sur-
vival does matter to those with advanced life-limiting illness,
equally and sometimes more important are: improved quality
of life; control of pain and other symptoms; family support;
knowing what to expect and having time to prepare; knowing
that—if their disease is not curable and is deteriorating—the
professionals are comfortable talking about death and dying;
and continuity and co-ordination of care [10].
To help patients make shared decisions as they approach
kidney failure, it is therefore important to have data on a wide
range of these outcomes—survival, quality of life and symp-
toms, and more—and tailor the information provided to the
priorities of the individual. Comparing experiences on dialysis
versus conservative care brings unique challenges, however,
and these must be appreciated when providing information to
patients. Studies tend to be small, retrospective and observa-
tional, with all the associated biases [11]. Particular challenges
are biased between the groups compared (where there are
unmeasured factors that determine which treatment the patient
receives, i.e. confounding by indication), and lead-time bias
(where it is hard to identify when dialysis would have been
started in patients on a conservative care pathway [12]).
E V I D E N C E O N C O M P A R A T I V E
E F F E C T I V E N E S S O F D I A L Y S I S A N D
C O N S E R V A T I V E C A R E
Two systematic reviews have looked at quality of life and symp-
toms in relation to dialysis and conservative care [13, 14]. In in-
dividual studies, physical quality of life has been shown to be
significantly lower in patients choosing conservative care rather
than dialysis, though mental quality of life is similar [15–17]; a
nice reminder that we are not comparing like with like in the
observational studies. Once on their chosen treatments, trends
in quality of life are broadly similar, though dialysis initiation
tends to be associated with a reduction in ‘satisfaction with life’
[17] and an increase in ‘effect of kidney disease’ and ‘burden of
kidney disease’ [18].
Prognosis is still an important consideration [9, 10, 19].
While there is clear evidence that, on average, those aged
>75 years treated with KRT can expect to live longer than those
managed conservatively [20], this survival advantage
diminishes when patients have higher comorbidity and poor
functional status. A systematic review of older people (mean
age across the studies ranged from 60.5 to 92.0 years) treated
with dialysis or conservative care found 89 studies conducted
between 1976 and 2014 including 294 921 older people with
kidney failure. Regardless of whether patients were managed
conservatively or with dialysis, initial 1-year survival was similar
at 73% [95% confidence interval (CI) 66–80%] in the dialysis
group and 71% (95% CI 63–78%) in the conservatively man-
aged group. At 2 years, however, the data suggest a survival ad-
vantage in the group managed with dialysis: 62% (95% CI 55–
69%) for the dialysis group and 44% (95% CI 36–53%) for those
managed conservatively. While dialysis initiation may be asso-
ciated with additional early risk, we should not over-interpret
these observational data as it is likely that the group of patients
with a better prognosis will have been chosen (or been medi-
cally advised to choose) to have dialysis. Even novel statistics
can only adjust for measured confounders; random allocation
of treatment groups is required if groups are to be balanced for
measured and unmeasured confounders [11]. There was also
residual heterogeneity in the survival data, both between the
studies and within the treatment groups. This likely reflects the
long period covered by the review, the changes in treatment
rates over time, differences in primary care referral patterns and
differences in the components of care provided by centres [20].
Finally, it should also be noted that only 724 (0.2%) of the
294 921 people studies received conservative care and that only
six studies directly compared survival on the two treatments.
T H E C O N S E R V A T I V E K I D N E Y M A N A G E M E N T
A S S E S S M E N T O F P R A C T I C E P A T T E R N S
S T U D Y
Although conservative care was being provided in the UK in
the early-2000s, the components provided and resources avail-
able varied greatly [21]. Guidance from the Department of
Health [22, 23] and kidney community [24–26] created a
framework for delivering higher quality conservative care in the
mid-2000s and it was in this context that the Conservative
Kidney Management Assessment of Practice Patterns Study
(CKMAPPS) was conceived and funded by the National
Institute for Health Research. Its purpose, stated from the be-
ginning, was twofold: to inform service development and design
of a future prospective multicentre study to evaluate the effec-
tiveness, cost-effectiveness and appropriateness of conservative
care compared with dialysis for treating elderly patients [27].
As a ‘complex intervention’ [28], conservative care needed
to be better understood before a future definitive study could be
undertaken. CKMAPPS therefore adopted a mixed-methods
approach, with five sub-studies—a patient interview study, a
staff interview study, a survey of renal units, a general practi-
tioner interview study, and a data linkage exercise [27]; the first
three of these playing a key part in informing the design of
Prepare for Kidney Care. The patient interviews highlighted the
contrasting beliefs held by older patients according to the treat-
ment option they have chosen and the renal unit they have
attended [29]. It called for better evidence about the effective-
ness of conservative care to support shared decision making
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[29]. In the staff interviews, most people stated that it was diffi-
cult to assess whether patients were suitable for renal replace-
ment therapy or conservative care. While many staff considered
it important for patients and their family to make their own
decisions based on the information they had been given, some
adopted a more directed approach and guided patients towards
a decision, particularly if they felt that patients would not bene-
fit from dialysis. Staff recognized that some patients changed
their minds over time, supporting the theory that decision-
making in this context is a process rather than a one-off event
[27].
The patient and staff interviews also determined the con-
tent of the renal unit survey [30]. This revealed that, although
erythropoietin, iron and symptom management were compo-
nents of almost all conservative care pathways, 40% of renal
units reported no psychology or social services support, and
50% could not offer home visits [30]. Most renal units (86%)
reported discussing the option of conservative care with all
patients at the age of >75 years and most (83%) reported us-
ing decision aids when discussing conservative care. Once
patients decided to have conservative care or dialysis, all renal
units reported that they subsequently reviewed that decision
[27, 30].
As data were not available on the numbers of patients opting
for conservative care in the UK, the survey asked clinical direc-
tors to estimate the percentage of the patients >75 years choos-
ing conservative care in their unit, with striking differences
reported. In 7 of the 42 responding renal units, <10% of
patients were thought to be choosing conservative care, whereas
in another six this figure was >80% (Figure 1) [27]. Although
based on the reports of clinical directors rather than data, this
raised the possibility of considerable geographic variation in
what patients were choosing, based on which kidney unit they
attended. While we could not be certain of the extent of the var-
iation, nor how much of the variation was warranted [31], it
seemed clear that equity in provision would require better
evidence to inform clinicians’ judgements and (if organizational
change was needed) to inform business cases.
B E Y O N D C K M A P P S : O B S E R V A T I O N A L
S T U D Y O R R C T ?
The final question in the CKMAPPS survey explored clinical
directors’ willingness to support future research in this area.
After a steer from the funder and evidence from the ProtecT
study that an embedded mixed-methods recruitment interven-
tion could make challenging trials a success [32, 33], this final
question asked about a future randomized controlled trial
(RCT) as well as the originally intended observational study.
The responses surprised many on the steering committee.
When asked if their unit would consider entering a patient aged
75 years with Stage 5 CKD into an RCT comparing conserva-
tive care with dialysis, more than half of clinical directors (42 of
65, 65%) indicated that they would, for selected patients [27].
Of those, 18 units said that their unit would definitely be willing
to participate in such a trial [27]. Only one unit reported they
would be unwilling to participate in such a trial. Responses to a
similar question about willingness to participate in an observa-
tional study were 60 of 65 (92%), 28 and 0, respectively [27].
I N I T I A L C R I T I C I S M O F T H E R C T A P P R O A C H
There have been two major criticisms of adopting an RCT ap-
proach to address this question. One raised from the very be-
ginning was whether it was ethical to randomly allocate
patients to prepare for dialysis or conservative care. The other,
which surfaced later and was less clearly expressed, related to
whether the evidence from an RCT approach was going to be
useful for decision making in such an individualized situation.
The ethics question turned out to be quite easily addressed.
First, the observational data showed no clear survival or quality
of life differences between patients choosing one treatment and
patients choosing the other. Recognizing that treatment re-
sponse is determined by more than a person’s age or list of diag-
noses, the clinical teams also had to confirm that neither
option—dialysis or conservative care—was inappropriate for a
particular patient before they were offered information about
the study. In addition, patients needed to have the mental ca-
pacity to make a shared decision to take part in the RCT and,
importantly, could only remain on a treatment allocated
through randomization if they retained that mental capacity. As
with any RCT, patients were free to decide to come off their al-
located treatment and return to usual care at any point after
randomization.
The second criticism is an often-cited criticism of RCTs
(and indeed observational studies) and relates to the way the
results are presented as net effects and applied as ‘evidence-
based medicine’ [34]. Indeed this had been a criticism of science
since the 19th century, as it tried to predict and explain all
actions and reactions—‘positivism’ [35]. In clinical research,
this manifests as results being presented as net, population-
average effects, ignoring individual differences. An extreme ex-
ample of this is explanatory trials done by the pharmaceutical























































Percentage of patients over 75 years choosing conservative care
N=41
FIGURE 1: Percentage of patients with Stage 5 CKD choosing con-
servative care based on a survey of clinical directors asked the ques-
tion: ‘In the calendar year 2012, what percentage of CKD5 patients
aged 75þ years opted for conservative care?’ [27].
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the same thing. The alternative approach is a ‘realist’ one, which
places greater emphasis on the range of outcomes that patients
themselves prioritize, and embeds qualitative research to under-
stand pathways and differences in responses and preferences
[34].
While Prepare for Kidney Care is powered to detect a ‘posi-
tivist’ 0.345 quality-adjusted life years (QALYs) difference be-
tween the two treatment arms, its extensive qualitative work,
numerous patient-centred secondary outcomes and embedded
position within a registry cohort study allows for a realist ap-
proach to interpreting the results and incorporating them in fu-
ture shared decision-making. Furthermore, a logic model was
developed setting out how each of the components of the
intervention might, it was hypothesized, produce the desired
outcome. This logic model served two purposes: it informed
decisions about the components of the intervention that were
essential and the ones which could be delivered more flexibly
by sites; and it determined the process data items that would
need to be collected to assess fidelity of delivery of the inter-
ventions and explore, post hoc, how the intervention had had
its effect (or not) [36]. In essence, the RCT approach is pro-
viding two groups of patients who should be similar in terms
of measured and unmeasured confounders, allowing an unbi-
ased comparison of the patient experience across a range of
outcomes, something that is impossible to achieve with obser-
vational data [11].
Assessed for eligibility
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3 Baseline and follow











1Eligibility including frailty and comorbidity assessed by research nurse
2Third phase of qualitative research, RCT participants only









management (N = 256)
Prepare for renal
dialysis (N = 256)
1. Assess
• Home visits
• Liaise with MDT
• Prepare for responsive management
2. Responsive management
• Routine support
  - Review in renal out-patients
  - Monthly telephone contact
  - One home visit by renal HCP per
  year
  - Communication with MDT
• Responsive support
  - In renal out-patients
  - In the community (telephone calls,
    home visits, emergency surgery
    appointments)
3. Supportive care
• Home visits
• Communication with MDT
1. Assess
• Clinic visits
• Liaise with MDT
• Prepare for renal dialysis
2. Renal dialysis
• Clinic visits
• Renal dialysis according
  to local protocols
• Communication with MDT
3. Supportive care
• Home visits
• Communication with MDT
FIGURE 2: Flow diagram for the Prepare for Kidney Care study. MDT, multidisciplinary team; HCP, healthcare professional.
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P R E P A R E F O R K I D N E Y C A R E : T H E S T U D Y
D E S I G N
The main study is a two-arm, superiority, parallel group, non-
blinded, individual-level, pragmatic RCT in multi-morbid, frail,
older people with advanced CKD, comparing the QALYs
gained >3 years after preparing for responsive management
versus preparing for dialysis. The term responsive management
was adopted for the conservative care arm for several reasons.
There was feedback from QuinteT team that the word conser-
vative may deter some patients, as it may not sound active
enough. This had previously been an issue in the ProtecT trial
[32]. It was also felt important that a distinction was made be-
tween conservative care as delivered locally and the protocol-
determined conservative care (including home visits) being de-
livered as part of the trial. This RCT is embedded in an observa-
tional cohort study, which is itself embedded in a national Stage
4/5 CKD registry (Figure 2). Full details of the trial—including
the power calculation and how enrolment works—are available
from the publically available protocol [37] and will be published
as a protocol paper before recruitment ends.
Qualitative and mixed-methods are integrated throughout
the trial to optimize its design and delivery. These are arranged
in three interconnected stages: optimizing the trial design and
intervention (Stage 1); optimizing recruitment (Stage 2); and
understanding the acceptability of the intervention and reasons
for non-compliance (Stage 3).
Someone will be eligible for the study if they have new or
existing Stage 5 CKD and are:
• aged 65þ years with a World Health Organization perfor-
mance status 3þ [38], or
• aged 65þ with a Davies comorbidity score 2þ [39], or
• aged 80þ [38].
Although almost all of the observational evidence comparing
conservative kidney care and dialysis is based on people
70 years and above, it was recognized by the trial management
group that there are patients aged 65–70 years for whom con-
servative care is considered clinically appropriate. For this rea-
son, and to ensure that the results of the trial addressed as many
questions as possible in relation to the provision of dialysis and
conservative care, it was agreed that for each person meeting
these criteria, the local clinical team must agree that neither pre-
paring for dialysis nor conservative care would inappropriate.
Patients are considered ineligible if unable to consent, consid-
ered medically unfit for dialysis, within 4 weeks of needing to
start dialysis, have had a previous kidney transplant, are ‘active’
on the kidney transplant waiting list or are being worked up for
the kidney transplant waiting list.
Family members, friends and carers are also being invited to
take part in a parallel study to assess carer burden.
T H E I N T E R V E N T I O N A N D S T A N D A R D O F
C A R E
A pragmatic approach was needed when designing the inter-
vention and agreeing the standard of care. Pre-trial qualitative
research was rapidly conducted with healthcare professionals to
understand current practice and feasibility of the proposed in-
tervention, as well as anticipated recruitment issues. Experts in
conservative care and dialysis met to agree the core components
and worked with the QuinteT team to present these in a bal-
anced way [40]. The nomenclature of the two treatment options
was carefully considered to minimize any influence on
recruitment.
For presentation purposes, both treatment options were di-
vided into three stages—an assess stage, a treatment stage and a
supportive stage (Table 1).
For patients allocated to prepare for responsive management, the as-
sess stage involves up to three home visits to undertake advanced care
planning. Once this is considered complete, the patient progresses to
the responsive management stage: clinic visits as usual, an annual
home visit to reassess the advance care plan and a review of symp-
toms by telephone in any month that they did not have a clinic visit or
home visit. Symptoms are managed optimally with medication, but if
things progress to a stage where they cannot be controlled then the
patient progresses to the supportive stage and has palliative care, as
best delivered locally.
For patients allocated to prepare for renal dialysis, the assess stage
involves coming to clinic as usual and agreeing the most appropriate
way to prepare for dialysis. This can include plans to start HD with an
arteriovenous fistula, graft or central venous catheter or have PD. If
and when kidney function and symptoms progress to the point that di-
alysis is being considered, the decision to start is made by the treating
clinician in agreement with the patient. Dialysis can be started incre-
mentally. If symptoms cannot be controlled on dialysis, the patient
can choose to progress to the supportive stage and receive palliative
care, as best delivered locally.
It is worth noting that not all patients will have a progressive
decline of the kidney function and need to decide to start dialy-
sis during the study—we anticipate significant numbers will
have stable function, decline slowly or die from other causes.
U N D E R S T A N D I N G R E C R U I T M E N T
The QuinteT Recruitment Intervention (QRI) was embedded
into Prepare for Kidney Care to support trial recruitment [33].
Recruitment ‘lessons learned’ are often reported towards the
end stages of an RCT, by which point there is limited opportu-
nity to support accrual to the trial in question. The QRI is
designed to rapidly investigate and address recruitment issues
in real-time, using methodology that originated in the ProtecT
study [41, 42]. The methods have been refined through applica-
tion to >40 RCTs [43, 44], with Prepare for Kidney Care the
first to apply these in a renal context.
C H A L L E N G E S A N D A C T I O N S T A K E N T O
A D D R E S S
As anticipated, recruitment to Prepare for Kidney Care has
been no easy feat. Challenges identified through the QRI have
varied across individual sites and over time, though several core
issues have emerged:
• some recruiters have been reluctant to discuss the trial
with patients deemed to have a treatment plan in place,
leading to around half of eligible RCT patients not being
approached. This issue is linked to renal units’ tendencies
to initiate discussions about end-stage CKD management
before estimated glomerular filtration rate falls below 15,
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with the intention of supporting shared decision-making
around future treatment. Recruiters’ reluctance and dis-
comfort around discussing the trial with these eligible
patients has stemmed from assumptions that decisions
are fixed, and concerns that re-opening discussions could
be confusing or distressing for patients. The time and
resources invested into supporting patients are also at
odds with the RCT recruitment discussion, which requires
communication of uncertainty and equipoise [45], and
• where eligible patients have been approached, audio-
recordings of recruitment discussions have revealed a ten-
dency for equipoise to be undermined through subtle
indications that one treatment arm (often response man-
agement) is more appropriate than the other (preparation
for renal dialysis).
Developing a nuanced understanding of recruitment issues
has allowed for tailored actions to be implemented iteratively as
sites have continued to open to recruitment. To address con-
cerns around re-opening treatment discussions, clinical
vignettes of patients who have entered the trial and extracts
from audio-recorded discussions have been used to gently chal-
lenge assumptions that patients have fixed decisions.
Challenges in conveying equipoise have been addressed
through individual feedback for recruiters who provide audio-
recordings of recruitment discussions, as well as study-wide
‘tips and guidance’ documents and ‘cue cards’ to support com-
munication. These documents have been kept under review to
ensure relevance as new evidence of recruitment issues emerge.
The above strategies have been reinforced through investigator
meetings, which have served as an opportunity to engender a
collaborative approach to delivering Prepare for Kidney Care.
The QRI strategies will continue through a combination of site-
specific and study-wide activities until the end of recruitment.
P R O G R E S S W I T H R E C R U I T M E N T
Prepare for Kidney Care was proposed to the Health
Technology Assessment programme of the National Institute
for Health Research and funded in September 2016. Work offi-
cially commenced in January 2017, with national research
ethics approval secured in May 2017. Recognizing the complex-
ity of the trial, site opening was arranged in two phases—an ini-
tial 4sites followed, 6 months later, by a further 12 sites. In fact,
6 sites opened in the initial phase and as of 31 March 2020,
there are 24 sites open with 246 of the required 512 (48%) par-
ticipants recruited. A further 103 participants have been
recruited to the observational study. Additional funding has
been secured from the funder to extend recruitment from the
original end date of 31 September 2019 to 31 March 2021 and
several additional sites are being worked up to open. However,
the COVID-19 pandemic is likely to change some of these time-
lines, with recruitment activity paused from 1 April 2020 to al-
low resources to be focused on the immediate public health
threat.
C O N C L U S I O N
There have historically been few RCTs to inform practice in
kidney clinics [46]. While there may be a number of explana-
tions for this, other specialties have faced similar challenges and
expanded and transformed the research they undertake. From a
position in the mid-1990s, when evidence relied on case series
and it was felt that ‘. . .the personal attributes that make a suc-
cessful surgeon differ from those needed for collaborative mul-
ticentre research. . .’ [47], surgical colleagues have transformed
the way they do research [48]. If we are to improve our evidence
base and reduce unwarranted variation in practice, the kidney
community must improve its ability to recognize uncertainty
and offer randomization to patients. As one of the Prepare for
Kidney Care investigators nicely put it when challenged: ‘I
don’t see what the problem is, you are just offering patients a
third option—they can choose to have dialysis, choose to have
conservative care or choose to take part in research’. It is hard
to argue with that.
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Table 1. The two treatment options in Prepare for Kidney Care
Prepare for renal dialysis Prepare for responsive management
• Assess
• Clinic visits/liaise with MDT
• Prepare for renal dialysis (HD or PD)
• Assess
• Home visits by renal HCP to assess needs and symptoms—up to three
• Renal dialysis
• Dialysis commenced as clinically appropriate
• 3–4 monthly assessments in clinic
• Liaison with other HCPs
• Responsive management
• Routine support: review in renal out-patients; one home visit by renal
HCP per year; telephone call from renal HCP monthly
• Responsive support: in renal out-patients
• In the community, by renal HCP and/or community teams
Supportive care: as delivered locally Supportive care: as delivered locally
MDT, multidisciplinary team; HCP, healthcare professional.
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